Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30663317 | 0.88 | GPR119 (0.47) | PARP1MEN1MAPTTSHRKMT2A | |
| SCHEMBL25093499 | 0.88 | GPR119 (0.47) | PARP1MEN1MAPTTSHRKMT2A | |
| SCHEMBL30493585 | 0.82 | USP30 (0.48) | PARP1MEN1MAPTTSHRKMT2A | |
| SCHEMBL30485431 | 0.82 | USP30 (0.48) | PARP1MEN1MAPTTSHRKMT2A | |
| SCHEMBL25917978 | 0.82 | USP30 (0.48) | PARP1MEN1MAPTTSHRKMT2A | |
| SCHEMBL28869895 | 0.81 | HDAC1 (0.50) | PARP1MEN1MAPTTSHRKMT2A | |
| SCHEMBL25319959 | 0.80 | GPR119 (0.52) | MEN1MAPTTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL25319965 | 0.80 | GPR119 (0.52) | MEN1MAPTTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL24649916 | 0.80 | HDAC1 (0.51) | PARP1MEN1MAPTTSHRKMT2A | |
| SCHEMBL24649851 | 0.80 | HDAC1 (0.51) | PARP1MEN1MAPTTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221987-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4464704-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Acerand Therapeutics (Hong Kong) Limited (HK) | 2024-11-20 | — | — | EP | disclosed |
| EP-4326720-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023134647-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 优领医药科技(香港)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134647-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 优领医药科技(香港)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-116425744-A | Piperazine-containing ring derivative, pharmaceutically acceptable salt thereof, and preparation method and application thereof | 优领医药科技(香港)有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220348574-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-11-03 | — | — | US | disclosed |
| WO-2022225934-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | PARP1 1/4885MEN1 3207/4885MAPT 3390/4885 |
| US-20250221987-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | PARP1, PARP11, PARP15 | PARP1 1/4885MEN1 2779/4885MAPT 1472/4885 |
| US-20220348574-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | PARP1 1/4885MEN1 3207/4885MAPT 3390/4885 |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | PARP1 1/4885MEN1 3207/4885MAPT 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.